Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the Metformin in Gestational diabetes (MiG) trial: responses to maternal metformin vs. insulin treatment

Barrett, Helen L., Gatford, Kathryn L., Houda, Candice M., De Blasio, Miles J., McIntyre, H. David, Callaway, Leonie K., Dekker Nitert, Marloes, Coat, Suzette, Owens, Julie A., Hague, William M. and Rowan, Janet A. (2013) Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the Metformin in Gestational diabetes (MiG) trial: responses to maternal metformin vs. insulin treatment. Diabetes Care, 36 3: 529-536. doi:10.2337/dc12-1097

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Barrett, Helen L.
Gatford, Kathryn L.
Houda, Candice M.
De Blasio, Miles J.
McIntyre, H. David
Callaway, Leonie K.
Dekker Nitert, Marloes
Coat, Suzette
Owens, Julie A.
Hague, William M.
Rowan, Janet A.
Title Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the Metformin in Gestational diabetes (MiG) trial: responses to maternal metformin vs. insulin treatment
Journal name Diabetes Care   Check publisher's open access policy
ISSN 0149-5992
1935-5548
Publication date 2013-03
Year available 2012
Sub-type Article (original research)
DOI 10.2337/dc12-1097
Volume 36
Issue 3
Start page 529
End page 536
Total pages 8
Place of publication Alexandria, VA, United States
Publisher American Diabetes Association
Collection year 2013
Language eng
Formatted abstract
OBJECTIVE This study was designed to compare glucose, lipids, and C-reactive protein (CRP) in women with gestational diabetes mellitus treated with metformin or insulin and in cord plasma of their offspring and to examine how these markers relate to infant size at birth.
RESEARCH DESIGN AND METHODS Women with gestational diabetes mellitus were randomly assigned to metformin or insulin in the Metformin in Gestational Diabetes trial. Fasting maternal plasma glucose, lipids, and CRP were measured at randomization, 36 weeks' gestation, and 6-8 weeks postpartum as well as in cord plasma. Women with available cord blood samples (metformin n = 236, insulin n = 242) were included.
RESULTS Maternal plasma triglycerides increased more from randomization to 36 weeks' gestation in women treated with metformin (21.93%) versus insulin (9.69%, P < 0.001). Maternal and cord plasma lipids, CRP, and neonatal anthropometry did not differ between treatments. In logistic regression analyses adjusted for confounders, the strongest associations with birth weight >90th centile were maternal triglycerides and measures of glucose control at 36 weeks.
CONCLUSIONS There were few differences in circulating maternal and neonatal markers of metabolic status and no differences in measures of anthropometry between the offspring of women treated with metformin and the offspring of women treated with insulin. There may be subtle effects of metformin on maternal lipid function, but the findings suggest that treating gestational diabetes mellitus with metformin does not adversely affect lipids or CRP in cord plasma or neonatal anthropometric measures.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online before print: 9 October 2012.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 05 Nov 2012, 11:53:17 EST by Marloes Dekker on behalf of Royal Brisbane Clinical School